New nirsevimab data analyses reinforce efficacy against RSV
New nirsevimab data analyses reinforce efficacy against RSVA prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the firs...